
The bone marrow cancer treatment Darzalex exceeded analysts' third quarter sales expectations with around DKK 850m.
The total market sales from the Johnson & Johnson-owned Janssen, which obtained Darzalex through an in-licensing agreement, could very well end up also exceeding the USD 5.6-5.9bn estimate that Genmab has included in its 2021 guidance.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app